SLAS2018 New Product Award Showcases Latest in Technological Advancement for Life Sciences Drug Discovery & Development
News Feb 08, 2018
Three organizations earned a SLAS New Product Award at SLAS2018 in San Diego for their innovative new products that have played an important role in the advancement of life sciences drug discovery and development.
The three winners of the New Product Award are: FORMULATRIX® for CONSTELLATION® Digital PCR System; iotaSciences, Ltd. for isoCell; and Labcyte for Echo 655T Acoustic Liquid Handler.
The CONSTELLATION® Digital PCR System by FORMULATRIX is a novel microfluidic platform that provides high-throughput absolute quantification of up to 5 target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications. Tom Rawlins, Director of Sales at FORMULATRIX accepted the award on behalf of the organization.
IotaSciences’ isoCell product intends to advance, automate and accelerate single-cell work using fluidic walls. Ed Walsh, CEO of iotaSciences, accepted the award on behalf of the organization.
Labcyte’s next evolution of the revolutionary Echo Liquid Handler Series, the Echo 655T Liquid Handler offers all the benefits associated with non-contact liquid transfer with the new ability to transfer directly from Echo Qualified sample tubes enabling an all acoustic workflow from sample store to screening assay. Mark Fischer-Colbrie, CEO of Labcyte, accepted the award on behalf of the organization.
A panel of judges reviewed 50 products onsite at SLAS2018 and announced the three winners during a press conference yesterday. Two past winners of the New Product award, Joe Maffei of Axion BioSystems and Manuela Beil-Peter of Analytik Jena also addressed the room.
“When you develop a new product, you never know how it will be received by the scientific community, and then when we heard we were awarded it really meant a lot to us,” said Beil-Peter, Head of Sales Indirect Channels at Analytik Jena. “It gave us the confirmation that we are on the right path, and that the new development met the actual market requirements.”
“It is not uncommon for new products launched at the SLAS International Conference and Exhibition to experience a buzz after being exposed to the conference audience,” said Vicki Loise, SLAS CEO. More than 6,000 influential life sciences discovery and technology professionals, including scientists, innovators, researchers, academics and students, engineers, informatics specialists, and business leaders from 40 countries are in attendance in San Diego.
“The annual SLAS International Conference and Exhibition has long been a platform for organizations to introduce innovative new products to the market. The conference provides them the exposure they need to help get their products off the ground and running, and gives life sciences researchers in academia, industry and government a first-hand look at innovative technologies designed to increase productivity, elevate data quality and reduce process cycle times.”
The SLAS New Product Award is an annual program recognizing new products that are commercially available for purchase within 90 days pre- and post-conference that are making a significant impact in the transformation of research that fosters advancements in life sciences drug discovery and development. Products are also considered for the New Product Award if they have launched outside the 90-day window but have experienced major enhancements.
SLAS2018 showcases scientific advances and state-of-the-art applications of new technologies via 144 podium presentations, 350+ poster presentations, 300+ multinational exhibitors, 20 short courses, a menu of personalized career services and an abundance of intelligent network-building opportunities. For more information about SLAS2018, visit www.slas2018.org
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE